PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced that it plans to initiate Phase 3 clinical studies with Hematide™ in chronic renal failure patients following recent discussions with the United States Food and Drug Administration (FDA) on the design of the Phase 3 clinical trial program. Hematide is the company’s lead drug in development for the treatment of anemia.
